Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SQAHG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Septuximab vedotin
|
|||||
| Synonyms |
Septuximab vedotin
Click to Show/Hide
|
|||||
| Organization |
University of California San Diego
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Ovarian cancer [ICD11:2C73]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Septuximab
|
Antibody Info | ||||
| Antigen Name |
Frizzled-7 (FZD7)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.03 nM | Positive FZD7 expression (FZD7+++/++) | ||
| Method Description |
Cells were seeded in a 96-well plate the day before drug treatment. MA-148, PA-1, and MA-148 FZD7-KO were incubated with the indicated drugs for 3 days.
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | OVCAR-3 cells (FZD7 overexpression) | CVCL_0465 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.00 nM | Positive FZD7 expression (FZD7+++/++) | ||
| Method Description |
Cells were seeded in a 96-well plate the day before drug treatment. MA-148, PA-1, and MA-148 FZD7-KO were incubated with the indicated drugs for 3 days.
|
||||
| In Vitro Model | Ovarian cystadenocarcinoma | MA148 cells | CVCL_AK47 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.00 nM | Positive FZD7 expression (FZD7+++/++) | ||
| Method Description |
Cells were seeded in a 96-well plate the day before drug treatment. MA-148, PA-1, and MA-148 FZD7-KO were incubated with the indicated drugs for 3 days.
|
||||
| In Vitro Model | Ovarian mixed germ cell tumor | PA-1 cells | CVCL_0479 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 25.00 nM | Negative FZD7 expression (FZD7-) | ||
| Method Description |
Cells were seeded in a 96-well plate the day before drug treatment. MA-148, PA-1, and MA-148 FZD7-KO were incubated with the indicated drugs for 3 days.
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | OVCAR-3 cells | CVCL_0465 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 60.00 nM | Negative FZD7 expression (FZD7-) | ||
| Method Description |
Cells were seeded in a 96-well plate the day before drug treatment. MA-148, PA-1, and MA-148 FZD7-KO were incubated with the indicated drugs for 3 days.
|
||||
| In Vitro Model | Ovarian cystadenocarcinoma | MA148 cells (FZD7 knock-out) | CVCL_AK47 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.